This option may not be for everyone, but it can work wonders for the right candidates
Use: To reduce the risk of sustained estimated eGFR decline, ESRD, and CV death in patients with type 2 diabetes mellitus and chronic kidney disease Usual Adult Dose for Metabolic Dysfunction-Associated Steatohepatitis Wegovy injection: Initial dose (weeks 1 through 4): 0.25 mg subcutaneously once a week Dose escalation: Weeks 5 through 8: 0.5 mg subcutaneously once a week Weeks 9 through 12: 1 mg subcutaneously once a week Weeks 13 through 16: 1.7 mg subcutaneously once a week If 2.4 mg is not tolerated: 1.7 mg subcutaneously once a week
GI side effects are common and usually transient
FDA Warns Novo Nordisk on Unreported Deaths CEO & Founder at LlamaLab FDA Cites 'Systemic Failures' in Novo Nordisk's Reporting of Ozempic Deaths The FDA issued a warning letter to Novo Nordisk on March 5, 2026, citing "systemic failures" in the company's adverse event reporting for its semaglutide and liraglutide drugs including at least two unreported patient deaths and a suicide case that had still not been submitted to the FDA as of the letter's date
Adjusting dosage according to individual response, as well as consistent tracking of blood glucose contents could help optimize cure while minimizing the likelihood of experiencing low blood sugar episodes
Zepbound, also known generically as tirzepatide, and Ozempic, which includes semaglutide, fall under the incretin mimetics family of drugs, which copy a gut hormone that regulates multiple functions in the body
